MA51276A - Traitement de la fibrose avec de l'inositol - Google Patents
Traitement de la fibrose avec de l'inositolInfo
- Publication number
- MA51276A MA51276A MA051276A MA51276A MA51276A MA 51276 A MA51276 A MA 51276A MA 051276 A MA051276 A MA 051276A MA 51276 A MA51276 A MA 51276A MA 51276 A MA51276 A MA 51276A
- Authority
- MA
- Morocco
- Prior art keywords
- inositol
- fibrosis
- treatment
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 title 1
- 229960000367 inositol Drugs 0.000 title 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT201700148902 | 2017-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51276A true MA51276A (fr) | 2021-04-21 |
Family
ID=61731767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051276A MA51276A (fr) | 2017-12-22 | 2018-12-20 | Traitement de la fibrose avec de l'inositol |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200390723A1 (fr) |
| EP (1) | EP3727359B1 (fr) |
| BR (1) | BR112020012687A2 (fr) |
| CA (1) | CA3085612A1 (fr) |
| ES (1) | ES2981316T3 (fr) |
| MA (1) | MA51276A (fr) |
| MX (1) | MX2020006451A (fr) |
| WO (1) | WO2019122119A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245755B1 (en) * | 1992-04-21 | 2001-06-12 | Curators Of The Unversity Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
| KR20010006027A (ko) | 1997-04-03 | 2001-01-15 | 포인트 바이오메디칼 코퍼레이션 | 방광내 약물 송달 시스템 |
| WO2011005886A1 (fr) * | 2009-07-07 | 2011-01-13 | Normoxys, Inc. | Méthode de réduction d'une résistance multimédicamenteuse à l'aide d'inositol tripyrophosphate |
| ITUA20163025A1 (it) * | 2016-04-29 | 2017-10-29 | Sochim Int S P A | Composizione per il trattamento della sindrome dell’ovaio policistico |
-
2018
- 2018-12-20 BR BR112020012687-0A patent/BR112020012687A2/pt not_active Application Discontinuation
- 2018-12-20 ES ES18822360T patent/ES2981316T3/es active Active
- 2018-12-20 MA MA051276A patent/MA51276A/fr unknown
- 2018-12-20 EP EP18822360.6A patent/EP3727359B1/fr active Active
- 2018-12-20 CA CA3085612A patent/CA3085612A1/fr active Pending
- 2018-12-20 MX MX2020006451A patent/MX2020006451A/es unknown
- 2018-12-20 US US16/955,220 patent/US20200390723A1/en not_active Abandoned
- 2018-12-20 WO PCT/EP2018/086182 patent/WO2019122119A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019122119A1 (fr) | 2019-06-27 |
| BR112020012687A2 (pt) | 2020-11-24 |
| ES2981316T3 (es) | 2024-10-08 |
| MX2020006451A (es) | 2020-11-06 |
| EP3727359A1 (fr) | 2020-10-28 |
| CA3085612A1 (fr) | 2019-06-27 |
| US20200390723A1 (en) | 2020-12-17 |
| EP3727359C0 (fr) | 2024-04-17 |
| EP3727359B1 (fr) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45192A (fr) | Traitement d'association | |
| MA46180A (fr) | Analogues de l'amyline | |
| EP3595694A4 (fr) | Construction de furtif immunitaire cas9 crispr | |
| MA46788A (fr) | Traitement de la fibrose | |
| EP3370721A4 (fr) | Traitement de l'ostéoarthrite | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| EP3325963A4 (fr) | Amélioration de l'estimation de globules | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| DK3635101T3 (da) | Manipulerede ligasevarianter | |
| EP3658139A4 (fr) | Méthodes de traitement de maladies hépatiques | |
| MA47820A (fr) | Traitement de la glycogénose de type iii | |
| EP3625971A4 (fr) | Traitement d'audio spatial | |
| EP3273955A4 (fr) | Traitement de maladies respiratoires | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| SI3720433T1 (sl) | Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni | |
| EP3378484A4 (fr) | Composition pharmaceutique pour le traitement de la fibrose cardiaque | |
| MA43106A (fr) | Traitement de l'oligo-ovulation associée à la stéatose hepatique | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| EP3454793A4 (fr) | Bobines de traitement d'anévrisme | |
| EP3347032A4 (fr) | Traitement de l'ascite | |
| EP3328384A4 (fr) | Traitement de la fibrose | |
| MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial |